Abstract 5602: Markers of hypoxic cells: Testing a pre-clinical detection assay

• Published in: Cancer research (Chicago, Ill.) Vol. 83; no. 7_Supplement; p. 5602
• Main Authors: Zayas, Beatriz, Rios, Karoline, Ortiz, Luis, Cox, Osvaldo
• Format: Journal Article
• Language: English
• Published: 04.04.2023
• DOI: 10.1158/1538-7445.AM2023-5602
• ISSN: 1538-7445

Abstract The proposed project aims to test the applicability of a novel set of patented organic compounds as markers of hypoxic circulating tumor cells (H-CTC) with potential pre-clinical relevance. Circulating tumor cells (CTC) are individual cells or clusters that can move from tumors to circulation invading other tissues. Often cells in the tumor need to adapt to low oxygen levels, generating a population of cells known as hypoxic cells that can survive low oxygen levels. These hypoxic cells can produce more cell junction proteins, augmenting connections between cells causing them to break away in clusters rather than individually. Clustered CTCs are much more efficient at metastasis formation. Release of CTC can also be stimulated by cancer treatments such as radiation and chemotherapy. To date, our research has generated in-vitro studies with a set of 3-nitrobenzazolo[3,2- a]quinolinium chloride salts (NBQS) demonstrating its capacity as markers of hypoxic human cancer cells in vitro. Comparison with the control Pimonidazole demonstrated the advantages of novel NBQ-TOM compounds as hypoxic marker. We here, aim to test the applicability of NBQS to identify hypoxic cells among circulating tumor cells (H-CTC). To date limited commercially CTC detection methods are available. Our application can be described as pre-clinical detection technology of hypoxic cancer cells serving also in cancer management. To determine the capacity of novel compound, NBQ-345 TOM as hypoxic fluorescent marker, colon tumor cells (COLO 205) are culture under hypoxic and aerobic environment and treated with NBQ-345TOM (25uM) for 24 hours. After treatment fluorescence is measured with an OPTIMA BMG Fluorimeter. Fluorescence emission results demonstrated significant formation of the NBQ-234 TOM fluorescent metabolite on hypoxic tumor cells in contrast to cells treated under aerobic environment. Also, fluorescence microscopy analysis of colon cancer cells treated for 24 hours with NBQ-345 TOM at hypoxic and aerobic conditions confirmed the stronger fluorescence generation at hypoxic conditions in contrast to cells at aerobic conditions. Citation Format: Beatriz Zayas, Karoline Rios, Luis Ortiz, Osvaldo Cox. Markers of hypoxic cells: Testing a pre-clinical detection assay. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5602.